Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End Financial Results
Date:2/17/2009

on for its product candidates and its discoveries. These and other risks which may impact management's expectations are described in greater detail under the caption "Risk Factors" in the company's quarterly report on Form 10-Q for the quarter ended September 30, 2008 as filed with the Securities and Exchange Commission (SEC) and other filings that the company makes with the SEC.

All forward-looking statements reflect the company's expectations only as of the date of this release and should not be relied upon as reflecting the company's views, expectations or beliefs at any date subsequent to the date of this release. Idenix anticipates that subsequent events and developments may cause these views, expectations and beliefs to change. However, while Idenix may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so.

                          IDENIX PHARMACEUTICALS, INC.

                 CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS

                     (IN THOUSANDS, EXCEPT PER SHARE DATA)

                                   (UNAUDITED)

                                     Three Months Ended      Years Ended
                                         December 31,        December 31,
                                       2008      2007      2008       2007
    Revenues:
      Collaboration revenue -
       related party                 $4,247   $12,573    $9,815    $64,751
      Other revenue                      21        29       234      3,277
        Total revenues                4,268    12,602    10,049     68,028

    Operating expenses (1):
      Cost of sales                     479     1,487     1,745      2,001
      Research and development       11,949    20,294    53,887     85,839
      Selling, general and
       administrative                 5,702     9,278    27,130     63,348
      Restructuring and
    
'/>"/>
SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Idenix Pharmaceuticals Restructures to Concentrate Efforts on HCV and HIV Programs
2. Idenix to Host Conference Call Discussing Third Quarter 2007 Financial Results
3. Idenix Pharmaceuticals to Present at BIO CEO & Investor Conference
4. Idenix to Host Conference Call Discussing Fourth Quarter 2007 Financial Results
5. Idenix Announces Data Presentations at the 43rd Annual Meeting of the European Association for the Study of the Liver (EASL)
6. Idenix Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference
7. Idenix Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
8. Idenix Pharmaceuticals to Present at the Seventh Annual Needham and Company, LLC Biotechnology and Medical Technology Conference
9. Idenix Pharmaceuticals Reports Second Quarter and Six Month Financial Results
10. Idenix Pharmaceuticals to Present at the Bank of America 2008 Specialty Pharmaceuticals Conference
11. Idenix to Host Conference Call Discussing Third Quarter 2008 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... ... ... Ralco is honored to announce that it is the primary sponsor of ... 5-9 in Marshall. The Ralco Enrichment Center is an interactive experience where the public ... daily lives. This unique exhibit also features a birthing center for fair goers to ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... has appointed Francois Vieillard as Sales & Marketing Director. , With more ... Vieillard will be responsible for reinforcing Tronics’ business development activities worldwide. He brings ...
(Date:7/30/2015)... (PRWEB) , ... July 30, 2015 , ... ... completion of a field clinical study of its canine osteoarthritis stem cell product, ... Aratana Therapeutics (Kansas City, KS) and will be marketed in the US by ...
(Date:7/30/2015)...  With over 60,000 customers across the globe, ISN improves the efficiency and effectiveness ... more than 60,000 safe and reliable contractors in over 80 countries. ... ... Over 60,000 Worldwide Customers In ... Headquartered in Dallas, TX , ISN has additional ...
Breaking Biology Technology:Ralco Announces Primary Sponsorship of Ralco Enrichment Center at Lyon County Fair 2Tronics appoints Francois Vieillard as Sales and Marketing Director 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 2VetStem Biopharma Successfully Completes Large Milestone Efficacy Study for its Flagship Canine Osteoarthritis Stem Cell Product 3ISN Reaches Over 60,000 Worldwide Customers 2ISN Reaches Over 60,000 Worldwide Customers 3
... Advanced Instruments, Inc . today introduced the ... automation-friendly osmometer for the biopharmaceutical industry."The ... designed for -- and completely redefines -- automation ... said Kelly Peterson, Product Manager, Advanced Instruments ( ...
... announced today,promising findings on the in vitro ... cancer developed on the basis of its ... both in vitro and in vivo models,Santaris ... inhibition of disease-associated microRNAs due to their ...
... April 20 Psylin Neurosciences Inc., ... Amylin Pharmaceuticals, Inc. and PsychoGenics, Inc. announced today ... novel compound, PSN0041, for the treatment of depression.(Logo: ... )PSN0041, a peptide from Amylin,s proprietary polypeptide hormone ...
Cached Biology Technology:Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 2Advanced Instruments Introduces 2020-BIO Multi-Sample Osmometer as First True Automation-Friendly Osmometer for the Biopharmaceutical Industry 3LNA-Based RNA oligonucleotides Potently Inhibit Cancer microRNAs 2Psylin Neurosciences Commences Development of Compound for Depression 2Psylin Neurosciences Commences Development of Compound for Depression 3
(Date:7/27/2015)... July 27, 2015  Synaptics Inc. (NASDAQ: ... solutions, today announced that Huawei has selected the ... for its stylish smartwatch. Huawei chose the state-of-the-art ... low power and highly responsive human interface qualities ... designers also required a classic round watch face ...
(Date:7/21/2015)... Sweden , July 21, 2015 Today, ... FPC1025. Already received as well as expected revenues in 2015 that ... in FPC,s communicated revenue guidance of approximately 2,200 MSEK for 2015. ... is a leading smartphone manufacturer in China ... selected FPC1 02 5 for Axon ...
(Date:7/13/2015)... July 13, 2015 Synaptics Inc. (NASDAQ: ... interface solutions, today announced sampling of ClearPad ® ... driver integration (TDDI) product targeting smartphones and tablets. ... combine Synaptics , best-in-class touch controller IP ... technology developed in the company,s Japan Design Center. ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3FPC's Touch Fingerprint Sensor FPC1025 in ZTE's Smartphone Axon 2Synaptics Announces Sampling of Second Generation TDDI Solutions 2Synaptics Announces Sampling of Second Generation TDDI Solutions 3
... In a discovery that seems counterintuitive, a study appearing ... has found that tendons in high-stress and strain ... frequently than low-stress tendons. This study sheds some light ... during aging. Tendons, composed of collagen and other ...
... a defect in cellular pathways that provides a new explanation ... known as craniosynostosis. Mutations of the WNT and ... regulate bone formation at the stem cell level, according to ... Science Signaling . "Our work contributes to the overall ...
... Rensselaer Polytechnic Institute and principal investigator Glenn Monastersky have been ... Stem Cell Science Program (NYSTEM) of the Empire State Stem ... the Center for Biotechnology and Interdisciplinary Studies (CBIS), said the ... excellence for basic stem cell research within the CBIS. ...
Cached Biology News:High-strain tendons repair less frequently 2Stem-cell disruption induces skull deformity, UR study shows 2Rensselaer Polytechnic Institute wins $2.45 million grant to support stem cell research 2
...
...
...
... silica based spin filter membrane to isolate DNA ... band is cut from an agarose gel and ... gel slice is melted irreversibly in a high ... to the silica spin filter membrane and washed ...
Biology Products: